Alembic Pharmaceuticals Ltd vs Caplin Point Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 768.05 as of 04 May 09:07 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Caplin Point Laboratories Ltd changed from 12.6 on March 2021 to 28.4 on March 2025 . This represents a CAGR of 17.65% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3057 crore on March 2021 to ₹ 15222 crore on March 2025 . This represents a CAGR of 37.86% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 576.45 crore as compare to the Sep '25 revenue of ₹ 564.43 crore. This represent the growth of 2.13% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 223.35 crore as compare to the Sep '25 ebitda of ₹ 219.56 crore. This represent the growth of 1.73% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Caplin Point Laboratories Ltd changed from ₹ 124.92 crore to ₹ 165.86 crore over 7 quarters. This represents a CAGR of 17.58% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Caplin Point Laboratories Ltd changed from 14.53 % on March 2021 to 13.43 % on March 2025 . This represents a CAGR of -1.56% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Caplin Point Laboratories Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,830 Cr while Market cap of Caplin Point Laboratories Ltd is 13,002 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd?

As of May 4, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹754.5. On the other hand, Caplin Point Laboratories Ltd stock price is INR ₹1710.6.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Caplin Point Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.